

Catherine M Viscoli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7781465/catherine-m-viscoli-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212
papers

26,272
citations

57
h-index

161
g-index

234
ext. papers

33,362
ext. citations

10.8
avg, IF

7.31
L-index

#	Paper	IF	Citations
212	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 2117-28	59.2	6064
211	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2012 , 35, 1364-79	14.6	2713
210	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
209	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 323-34	59.2	1956
208	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015 , 38, 140-9	14.6	1906
207	Oral antihyperglycemic therapy for type 2 diabetes: scientific review. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 360-72	27.4	789
206	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016 , 374, 1321-31	59.2	654
205	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015 , 58, 429-42	10.3	496
204	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018 , 41, 356-363	14.6	365
203	Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2668-75	27.4	355
202	Clinical practice. Management of hyperglycemia in the hospital setting. <i>New England Journal of Medicine</i> , 2006 , 355, 1903-11	59.2	286
201	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 90-100	3.3	283
200	National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. <i>JAMA Internal Medicine</i> , 2014 , 174, 1116-24	11.5	270
199	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a EditorsPExpert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
198	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018 , 137, 119-129	16.7	252
197	Metformin: new understandings, new uses. <i>Drugs</i> , 2003 , 63, 1879-94	12.1	233
196	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 610-621	18.1	217

195	The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. <i>Muscle and Nerve</i> , 2001 , 24, 1229-31	3.4	198
194	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. <i>Diabetes Care</i> , 2017 , 40, 468-475	14.6	181
193	Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. <i>Cancer</i> , 2001 , 91, 443-54	6.4	178
192	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME \square trial. <i>European Heart Journal</i> , 2018 , 39, 363-370	9.5	171
191	Metformin: clinical use in type 2 diabetes. <i>Diabetologia</i> , 2017 , 60, 1586-1593	10.3	170
190	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. <i>Circulation</i> , 2019 , 140, 1463-1476	16.7	163
189	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney International</i> , 2018 , 94, 26-39	3.9	160
188	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	27.4	155
187	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. <i>Circulation</i> , 2008 , 117, 574-84	16.7	154
186	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME \square). <i>Cardiovascular Diabetology</i> , 2014 , 13, 102	8.7	153
185	The stroke prognosis instrument II (SPI-II) : A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. <i>Stroke</i> , 2000 , 31, 456-62	6.7	151
184	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019 , 21, 665-675	12.3	145
183	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018 , 379, 1107-1117	59.2	143
182	Clinical practice. Diagnosis of diabetes. <i>New England Journal of Medicine</i> , 2012 , 367, 542-50	59.2	134
181	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , 2020 , 141, 90-99	16.7	130
180	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018 , 41, e4-e5	14.6	116
179	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019 , 139, 1384-1395	16.7	115
178	Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> , 2020 , 142, 1028-1039	16.7	105

177	The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , 2019 , 21, 1402-1411	12.3	103
176	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. <i>Circulation</i> , 2018 , 137, 405-407	16.7	96
175	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017 , 48, 1218-1225	6.7	86
174	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1801-2	59.2	85
173	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2755-2769	12.7	81
172	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020 , 41, 2379-2392	9.5	80
171	Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. <i>Diabetologia</i> , 2018 , 61, 2118-2125	20.5	79
170	MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
169	SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
168	A Single Virtual Consult Reduces Severe Hyperglycemia in Patients Admitted with COVID19 Infection. <i>Journal of the Endocrine Society</i> , 2021 , 5, A335-A335	0.4	78
167	Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac Transplantation. <i>Journal of the Endocrine Society</i> , 2021 , 5, A383-A383	0.4	78
166	Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. <i>Journal of the Endocrine Society</i> , 2021 , 5, A570-A571	0.4	78
165	Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. <i>Diabetes Care</i> , 2005 , 28, 1680-9	14.6	77
164	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. <i>European Journal of Heart Failure</i> , 2017 , 19, 43-53	12.3	76
163	Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 192, 387-93	6.4	75
162	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018 , 138, 1904-1907	16.7	75
161	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1637-1645	3.9	73
160	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , 2021 , 143, 298-309	16.7	69

159	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. <i>Circulation</i> , 2020 , 141, 100-111	16.7	68
158	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 133-143	3.3	63
157	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME ² randomised trial. <i>Diabetologia</i> , 2018 , 61, 1712-1723	10.3	58
156	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020 , 142, 1040-1054	16.7	52
155	Analysis from the EMPA-REG OUTCOME trial ² indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019 , 96, 489-504	9.9	47
154	SGLT2 inhibitors in the management of type 2 diabetes. <i>Endocrine</i> , 2016 , 53, 364-72	4	47
153	Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 914-922	5.6	46
152	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 2269-2279	4 ⁰	46
151	Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. <i>Postgraduate Medicine</i> , 2004 , 115, 69-70, 73-6	3.7	45
150	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 811-818	7.9	44
149	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> , 2016 , 39, 1684-92	14.6	43
148	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. <i>Circulation</i> , 2017 , 135, 1882-1893	16.7	42
147	Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. <i>JAMA Neurology</i> , 2019 , 76, 526-535	17.2	42
146	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. <i>Diabetes Care</i> , 2014 , 37, 1924-30	14.6	40
145	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020 , 41, 3402-3418 ⁴⁰	9.5	40
144	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 631-639	6.7	39
143	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1217-1225	12.3	39
142	Type 2 Diabetes Mellitus and Insulin Resistance: Stroke Prevention and Management. <i>Current Treatment Options in Neurology</i> , 2004 , 6, 443-450	4.4	38

141	The prevention of type 2 diabetes mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 199-219, viii	5.5	36
140	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 499-507	16.2	35
139	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME ² trial. <i>Age and Ageing</i> , 2019 , 48, 859-866	3	34
138	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019 , 139, 1458-1460	16.7	34
137	Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. <i>American Heart Journal</i> , 2014 , 168, 823-9.e6	4.9	34
136	Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME ² . <i>Diabetologia</i> , 2018 , 61, 1522-1527	10.3	33
135	Characterization and implications of the initial estimated glomerular filtration rate \hat{eGFR} upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021 , 99, 750-762	9.9	33
134	Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). <i>Circulation</i> , 2018 , 137, 455-463	16.7	32
133	Diabetes mellitus in pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2004 , 31, 907-33, xi-xii	3.3	31
132	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 126-135	12.3	30
131	Approach to diabetes management in patients with CVD. <i>Trends in Cardiovascular Medicine</i> , 2016 , 26, 165-79	6.9	28
130	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. <i>Circulation</i> , 2018 , 138, 1210-1220	16.7	28
129	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1073-1078	6.7	27
128	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 713-715	7.4	27
127	Treatment of diabetes in the elderly. Addressing its complexities in this high-risk group. <i>Postgraduate Medicine</i> , 2005 , 118, 19-26, 29	3.7	26
126	Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1121-1127	6.7	25
125	Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience. <i>Circulation</i> , 2016 , 134, 1405-1408	16.7	24
124	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021 , 44, 586-594	14.6	24

123	Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2016 , 39, e99-e101	14.6	23
122	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 254-264	7.9	23
121	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021 , 42, 3727-3738	9.5	22
120	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , 2015 , 38, e128-9	14.6	21
119	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1128-1132	14.6	21
118	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019 , 139, 366-375	16.7	21
117	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , 2020 , 142, 1623-1632	16.7	20
116	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME ² trial. <i>European Heart Journal</i> , 2020 , 41, 209-217	9.5	20
115	Understanding Contemporary Use of Thiazolidinediones. <i>Circulation: Heart Failure</i> , 2019 , 12, e005855	7.6	19
114	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1247-1258	12.3	19
113	Bladder cancer in the EMPA-REG OUTCOME trial. <i>Diabetologia</i> , 2017 , 60, 2534-2535	10.3	18
112	Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. <i>SAGE Open Medicine</i> , 2015 , 3, 2050312114568476	2.4	17
111	Metabolic Management during Critical Illness: Glycemic Control in the ICU. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 859-69	3.9	17
110	Evidence supports prediabetes treatment. <i>Science</i> , 2019 , 364, 341-342	33.3	16
109	Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. <i>Diabetes Care</i> , 2020 , 43, 244-246	14.6	16
108	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 1599-1601	16.7	16
107	The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: a prospective observational study. <i>Journal of Critical Care</i> , 2014 , 29, 1052-6	4	15
106	Decade-long trends in mortality among patients with and without diabetes mellitus at a major academic medical center. <i>JAMA Internal Medicine</i> , 2014 , 174, 1187-8	11.5	15

105	Current Therapies for the Medical Management of Diabetes. <i>Obstetrics and Gynecology</i> , 2016 , 127, 780-794	14	15
104	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , 2018 , 203, 25-29	4.9	15
103	Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1207-1214	6.7	14
102	Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2140-2147	6.7	14
101	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	14
100	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 949-959	18.1	14
99	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 617-628	12.3	14
98	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 601-613	12.3	14
97	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. <i>JAMA Neurology</i> , 2017 , 74, 1319-1327	17.2	13
96	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019 , 42, e53-e55	14.6	13
95	Recognition of incident diabetes mellitus during an acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 260-7	5.8	13
94	Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. <i>ESC Heart Failure</i> , 2020 , 7, 1966-1971	3.7	13
93	Minimization of Hypoglycemia as an Adverse Event During Insulin Infusion: Further Refinement of the Yale Protocol. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 480-6	8.1	13
92	Management of hypercalcemia. Diagnostic workup, therapeutic options for hyperparathyroidism and other common causes. <i>Postgraduate Medicine</i> , 2004 , 115, 27-36	3.7	13
91	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020 , 43, 3007-3015	14.6	13
90	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	16.7	13
89	How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2015 , 108, 179-86	7.4	12
88	Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2015 , 9, 1227-35	4.1	12

87	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018 , 202, 39-48	4.9	12
86	Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. <i>Diabetes Care</i> 2016;39(Suppl. 1):S52-S59. <i>Diabetes Care</i> , 2016 , 39, e88-9	14.6	11
85	Glycemic targets: what is the evidence?. <i>Medical Clinics of North America</i> , 2015 , 99, 47-67	7	10
84	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 720-725	6.7	10
83	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1141-1150	6.7	9
82	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1085-1093	12.3	9
81	A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1853-1860	2.5	8
80	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	8
79	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020 , 43, 2878-2881	14.6	8
78	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 632-643	12.3	8
77	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. <i>Circulation: Heart Failure</i> , 2020 , 13, e007879	7.6	7
76	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020 , 9, 56-59	2.5	7
75	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000046	4.5	7
74	Metformin therapy in patients with type 2 diabetes complicated by heart failure. <i>American Heart Journal</i> , 2007 , 154, e45	4.9	7
73	Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2335-2347	6.7	7
72	Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 425-433	6.7	7
71	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 137-152	5.5	6
70	Using the glucometrics website to benchmark ICU glucose control before and after the NICE-SUGAR study. <i>Journal of Diabetes Science and Technology</i> , 2014 , 8, 918-22	4.1	6

69	Glycemic management of diabetes in the perioperative setting. <i>International Anesthesiology Clinics</i> , 2002 , 40, 77-93	0.6	6
68	Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. <i>Stroke</i> , 2018 , STROKEAHA118022745	6.7	6
67	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021 , 23, 1662-1672	12.3	6
66	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 135-141	6.7	6
65	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <i>American Heart Journal</i> , 2015 , 170, 753-759.e2	4.9	5
64	Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. <i>Neuroepidemiology</i> , 2018 , 50, 137-143	5.4	5
63	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
62	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 ,	3.7	5
61	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 200	8.7	5
60	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1426-1430	6.7	5
59	Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. <i>Stroke</i> , 2019 , 50, 713-717	6.7	5
58	Diabetes prevention and cardiovascular complications. <i>Diabetologia</i> , 2019 , 62, 2161-2162	10.3	4
57	Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 21-27	5.5	4
56	Implications of the EMPA-REG Trial for Clinical Care and Research. <i>Current Diabetes Reports</i> , 2016 , 16, 131	5.6	4
55	Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents. <i>Journal of Diabetes and Its Complications</i> , 2012 , 26, 333-8	3.2	4
54	Type 2 diabetes therapy. A pathophysiologically based approach. <i>Postgraduate Medicine</i> , 2002 , 111, 83-4, 87-92, 95	3.7	4
53	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 , 8, 2603-2607	3.7	4
52	Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1173-1181	6.7	4

51	Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018 , 9, 217-222	4.5	4
50	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021 , 27, 888-895	3.3	4
49	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 184-197	7.9	4
48	Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging. <i>Endocrine</i> , 2020 , 68, 489-501	4	3
47	Hypoglycemia in type 2 diabetes: understanding patients and physicians' knowledge and experience. <i>Endocrine</i> , 2018 , 60, 435-444	4	3
46	Hyperglycemia grand rounds: descriptive findings of outcomes from a continuing education intervention to improve glycemic control and prevent hypoglycemia in the hospital setting. <i>Hospital Practice (1995)</i> , 2015 , 43, 270-6	2.2	3
45	Clitoral epidermoid cyst presenting as pseudoclitomegaly of pregnancy. <i>AJP Reports</i> , 2013 , 3, 57-62	1.2	3
44	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019 , 9, e029098	3	3
43	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3
42	Improving Type 2 Diabetes Patient Health Outcomes with Individualized Continuing Medical Education for Primary Care. <i>Diabetes Therapy</i> , 2016 , 7, 473-81	3.6	3
41	The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone. <i>Journal of Diabetes</i> , 2016 , 8, 607-9	3.8	3
40	Association of Baseline Characteristics With Insulin Sensitivity and β Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021 , 44, 340-349	14.6	3
39	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1035-1039	3.2	2
38	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , 2021 , 36, 108101	3.2	2
37	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008837	7.6	2
36	Rationale and Design of a Cluster-Randomized Pragmatic Trial Aimed at Improving Use of Guideline Directed Medical Therapy in Outpatients with Heart Failure: PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF). <i>American Heart Journal</i> , 2021 , 244, 107-107	4.9	2
35	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
34	Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. <i>International Journal of Stroke</i> , 2019 , 14, 639-645	6.3	2

33	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2775-2784	6.7	2
32	Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> 2016;39:1684-1692. <i>Diabetes Care</i> , 2017 , 40, e47-e48	14.6	1
31	Adherence to study drug in a stroke prevention trial">. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020 , 29, 105048	2.8	1
30	Taking care of volunteers in a stroke trial: a new assisted-management strategy. <i>Stroke and Vascular Neurology</i> , 2016 , 1, 108-114	9.1	1
29	Litigation seeking access to data from ongoing clinical trials: a threat to clinical research. <i>JAMA Internal Medicine</i> , 2014 , 174, 1502-4	11.5	1
28	A Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients with Type 2 Diabetes at High Cardiovascular Risk (the SIMPLE Trial).. <i>Diabetes</i> , 2022 ,	0.9	1
27	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.. <i>EClinicalMedicine</i> , 2022 , 43, 101240	11.3	1
26	Chromium Picolinate for the Prevention of Type 2 Diabetes 2011 , 3, 34-40		1
25	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , 2022 , 10, 52-64	7.9	1
24	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021 , 1	2.5	1
23	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. <i>Diabetes</i> , 2020 , 69, 131-LB	0.9	1
22	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. <i>European Cardiology Review</i> , 2021 , 16, e11	3.9	1
21	A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016 , 25, 1705-1712	2.8	1
20	Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab124	0.9	1
19	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.. <i>Diabetes Research and Clinical Practice</i> , 2022 , 109837	7.4	1
18	Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 306-318	7.9	1
17	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.. <i>JACC: Heart Failure</i> , 2022 , 10, 104-118	7.9	0
16	Comprehensive Genomic Characterization of A Case of Granular Cell Tumor of the Posterior Pituitary Gland: A Case Report.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 762095	5.7	0

15	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. <i>Sleep and Breathing</i> ,	3.1	0
14	Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". <i>Circulation</i> , 2017 , 136, 1567-1568	16.7	
13	Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?. <i>Circulation</i> , 2019 , 139, 2383-2385	16.7	
12	An Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response. <i>Journal of Clinical Epidemiology</i> , 2019 , 107, 129	5.7	
11	The authors reply. <i>Kidney International</i> , 2020 , 97, 213-214	9.9	
10	Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". <i>Stroke</i> , 2017 , 48, e256-e257	6.7	
9	Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. <i>Diabetes Care</i> 2020;43:244-246. <i>Diabetes Care</i> , 2020 , 43, e159	14.6	
8	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021 , 14, 35	3.2	
7	Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> 2020;43:3007-3015. <i>Diabetes Care</i> , 2021 , 44, e137-e138	14.6	
6	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies 2016 , 471-492		
5	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i487-i487	4.3	
4	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 669-670	59.2	
3	Somatic NF1 mutations in pituitary adenomas: Report of two cases. <i>Cancer Genetics</i> , 2021 , 256-257, 26-30.3		
2	Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. <i>Diabetes Spectrum</i> , 2021 , 34, 235-242	1.9	
1	Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007 , 36 Suppl 2 Incretin, 2-17	5.5	